Biotech Research Methods

how do clinical trials work

How do clinical trials work? A treatment that looks promising in the lab is tested in people in stages, under a written protocol and ethics oversight. Your first choice: understand a trial, read a paper, or follow new studies.

Each choice leads to a different part of this guide. Trial mechanics explain why a result can be trusted. Paper-reading habits tell you how much weight a single report deserves. Search habits keep you current without relying on headlines. The lab-method guides at the end cover the techniques that produce the evidence before any person is enrolled.

Choose your starting point

Start with the question you are trying to answer, because biotech evidence comes in layers and each layer answers a different question. Lab and animal work asks whether an idea is worth testing. Early human studies ask whether a treatment is tolerated. Larger trials ask whether it works. Published papers and peer review are how those results reach the public, and a search tool is how you find them.

  • You want to understand how a trial is run. Read the next two sections on protocols, oversight, randomization and blinding, then the phase comparison. This suits patients, relatives and students trying to make sense of a trial announcement.
  • You have a paper or press release in front of you. Go to the sections on reading a paper and peer review, then use the checklist. This suits anyone who needs to decide quickly whether a claim is solid.
  • You want to follow a field over time. Go to the section on finding research in PubMed, then pick the lab-method guides that match the field you follow.
  • You want to know how the underlying experiments work. Skip to the final section, which points to guides on blots, assays, cytometry, screening and model systems.

Three criteria help you choose where to spend time. First, how close the evidence is to people: a result in cells or animals is a different kind of claim from a result in a human trial. Second, how the comparison was made, since a result with no fair comparison is a weaker signal. Third, whether anyone independent looked at the work before it appeared. The sections below take these in turn.

How a clinical trial begins and who oversees it

A clinical trial is the step where a treatment that has looked promising in preclinical work is tested in people. The National Heart, Lung, and Blood Institute notes that the idea for a clinical trial often starts in the lab, and promising treatments move from lab and animal tests into trials. If you want to see how lab models differ before the human stage, in vitro vs in vivo explains what each kind of model can and cannot show.

The lab-to-human link is not abstract. The FDA explains that in Phase 1, researchers adjust dosing schemes based on animal data to find the dose people tolerate. So when you read a Phase 1 report, the preclinical work is part of the reasoning behind the dose, and a weak preclinical case should make you more cautious about everything that follows.

The protocol: the plan every trial follows

Every trial follows a plan called a protocol. According to NHLBI, the protocol covers the tests, eligibility, duration, goals, data collected and protections for participants. For a reader, the protocol is the yardstick. A result is most convincing when the paper reports the same goals the protocol set out in advance, and less convincing when the paper emphasises an outcome that was never a stated aim.

Ethics review and regulator review

Oversight happens at two levels. At the trial site, NHLBI explains that governing bodies called Institutional Review Boards approve protocols and are responsible for ensuring participant safety. At the regulatory level, a trial of a new drug in the United States needs clearance first: Cleveland Clinic states that clinical trials in the U.S. require FDA approval before researchers can start the trial. The FDA adds that its review team has 30 days to review the original investigational new drug submission, as described in its guide to clinical research.

When you evaluate a study, a mention of an ethics board and regulatory clearance is a baseline, not a mark of quality. It tells you the plan was reviewed before people were enrolled. It does not tell you the treatment worked.

Sample handling is one routine step behind trial data. A yellow box and a blue-lidded tray sit on the bench beside the technician; the photo is illustrative and does not depict a specific trial.

Design features that make trial results believable

Three design choices do most of the work in separating a believable trial from a suggestive one: who is allowed in, how people are assigned to groups, and who knows the assignments. Check each before you accept a headline result.

Eligibility: who the result applies to

The National Cancer Institute states that every clinical trial has requirements that must be met for you to join, such as health, medical history, age and treatment history. For a reader this is a limit on how far a result travels. A treatment that worked in a narrowly defined group may behave differently in people who would have been excluded, so match the trial population to the people the claim is about.

Randomization: assignment by chance

NCI explains that randomization, in which people are assigned to groups by chance alone, helps prevent bias, and that a computer is most often used to assign people to groups. The reasoning is straightforward: if researchers or participants chose the groups, differences between the groups could come from those choices rather than the treatment. When a report describes a comparison without saying how groups were formed, treat the result as weaker.

Blinding: who knows what

Blinding limits another source of bias. In double-blind studies, as NHLBI describes, neither the participant nor the research team is told what the participant is given; only the pharmacist knows. This matters most when the outcome involves judgement or self-report, because expectations can shape what people notice and record. If a trial could not be blinded, look for how the authors tried to compensate and whether the outcome was objectively measured.

  • Choose to trust more when the paper states the eligibility rules, the method of assignment and who was blinded, and these match the protocol.
  • Choose to wait when the paper gives a promising result but leaves out how groups were formed or who knew the assignments.
  • Choose a different source when a news item describes an effect but names no trial, no phase and no group size.

How to read a scientific paper

Read a paper as an argument with evidence, not as a verdict. A workable order is purpose first, design second, participants third, results fourth and conclusions last, and the conclusions are judged against everything before them. This order protects you from the headline and abstract framing that most readers absorb first.

Begin with why the study was done. Cleveland Clinic’s list of questions for people considering a trial begins with why the study is being done, and the same question works on any paper. A clear, specific purpose usually means a clear design. A vague purpose often means the analysis was shaped after the data arrived.

Then ask what kind of study it is and where it sits among the trial phases, because the phase sets what the study can legitimately claim. A small early study can speak to tolerance and dose; it cannot settle effectiveness. The phase section below puts numbers on this.

  • Read the methods before the results. The methods are where randomization, blinding and eligibility appear, and they decide how much the results can bear.
  • Match the conclusion to the evidence. If the authors claim more than the group, phase or comparison supports, take the evidence rather than the claim.
  • Note what kind of model was used. Findings from cells, tissue models or animals are earlier-stage evidence than human trial data. For 3D lab models, Spheroids vs Organoids: Which 3D Model Should You Use in 2026? A Practical Comparison – Biolifetechnologies shows how model choice changes what a result means.

Peer review: what it is and what it tells you

Peer review is a process in which experts review a report before it is published, checking the analysis and conclusions, as NHLBI defines it. In practice it means that people with relevant expertise examined the work before it reached readers.

Use that as a filter, not a guarantee. A peer-reviewed paper has been looked at by outsiders, which is a better starting point than an unreviewed claim. It does not remove the need for your own checks on design, population and conclusions. Equally, the absence of peer review is a reason to ask where the claim comes from and what evidence sits behind it, not proof the claim is wrong.

  • Peer-reviewed report: suits claims you plan to rely on or repeat, as long as the design and conclusions still line up.
  • Press release or summary: suits leads only. Trace it back to the underlying report before acting on it.
  • Early-stage lab result: read with the model type in mind, since a cell-culture or computational finding is a hypothesis for later testing.

Finding and following research with PubMed

PubMed is the practical tool for tracking published work, and one fact makes it especially useful for trials. NHLBI notes that published study results can be found by searching for the study’s official name or Protocol ID number. If a news story or a trial listing gives either, search it in PubMed to find the peer-reviewed report instead of relying on a summary.

Build a routine that fits how closely you follow the field.

When a result matters to a decision, look for more than one report. A single trial is a data point; agreement across trials is evidence.

Which phase are you reading about?

Phase determines what a result can claim, so identify it before judging the data. Group sizes differ between sources: NCI describes Phase 1 trials as a small group of people (around 15 to 30) and Phase 2 as 50 to 100 people, while the FDA gives wider ranges. Treat these as typical ranges, not fixed rules, and read the actual enrolment in the paper in front of you.

Phase Typical participants Typical length What it can tell you Share of drugs moving on Planning use
Phase 1 20 to 100 healthy volunteers or people with the disease or condition Several months Safety and dosage Approximately 70% Read as a safety and dose signal; do not read as proof the treatment works.
Phase 2 Up to several hundred people Several months to 2 years Treatment tested in more people than in Phase 1 Approximately 33% Treat as an early signal; most drugs do not move on from here.
Phase 3 300 to 3,000 volunteers who have the disease or condition 1 to 4 years Confirms effectiveness and safety Approximately 25-30% The strongest pre-approval evidence; weigh it above earlier phases.
Phase 4 Carried out after FDA approval Not specified Safety and efficacy monitoring in the general population Not applicable Useful for real-world safety once a treatment is in use.

Figures are from the FDA’s overview of clinical research, with the Phase 3 purpose confirmed by Cleveland Clinic.

The progression figures are the most useful decision tool in the table. Only some drugs move on from each phase, so a promising Phase 1 or Phase 2 report is a reason to keep watching, not a reason to expect an approved treatment. By contrast, a positive Phase 3 result in a large group is far better evidence, though you should still check the design features above.

  • Phase 1 report: look for dose, side effects and how the group was chosen. Skip any effectiveness claim.
  • Phase 2 report: look for a clear comparison and an honest account of the group size before treating the result as a trend.
  • Phase 3 report: look for randomization, blinding and an outcome that matters to patients.
  • Phase 4 report: look for what monitoring in the general population adds beyond the approval trials.

Checklist for evaluating a biotech study

Work through these points in order. Stop and downgrade your confidence at the first one you cannot answer from the paper.

  1. Purpose: is the reason for the study stated plainly, and do the reported outcomes match it?
  2. Protocol: does the paper describe the plan, including goals and eligibility, in a way consistent with how the results are framed?
  3. Oversight: is there a mention of ethics board approval, and for drug trials, regulatory clearance?
  4. Population: do the eligibility rules fit the people the claim is about?
  5. Assignment: were people assigned to groups by chance, and was the method of assignment described?
  6. Blinding: who knew the assignments, and does the outcome depend on judgement?
  7. Phase and size: does the conclusion stay within what that phase can show?
  8. Review: was the report peer-reviewed, and can you find it by name or Protocol ID in PubMed?
  9. Model type: is the evidence from people, animals, cells or computation, and is the claim worded to match?

If the answers are mostly yes, the study is a sound basis for forming a view. If several are no, keep the finding as a lead and look for a better-designed study.

Lab methods and models behind the evidence

Before a trial can begin, laboratory methods generate the data that justifies it, and the same methods appear in many biotech papers. Learning how they work makes the results sections much easier to read. These guides cover the techniques most often behind headline findings.

Results often arrive as tables on a screen. Checking the table against the methods is the habit that matters; the image is a stock illustration, not a particular study.

Assays and measurement techniques

  • Protein detection: learn how does a western blot work and how does elisa work to read protein-level results with confidence.
  • Cell analysis: how does flow cytometry work explains the plots that appear in many cell biology papers.
  • Large-scale testing: what is high throughput screening shows how compound candidates are narrowed before any human study.

Models and computation

Pick the guide that matches the method named in the paper you are reading. A paper that rests on a single technique is only as strong as that technique’s controls, which is easier to judge once you know how the technique works.

Automated instruments with attached monitors are typical of modern research labs. A desk with a keyboard sits along the right side; the scene is illustrative only.

Frequently asked questions

Do participants pay for care in a clinical trial?

Typically not for the care that is part of the trial. The University of California Health guide says participants do not pay for the care they receive as part of the trial, though an insurer may be billed for some costs. Ask the research team exactly what is covered.

Can someone leave a trial after joining?

Yes. NHLBI states that participants can withdraw at any time, and participation is voluntary from the start.

What do researchers explain before someone joins?

Researchers talk through the specific risks the trial may involve before enrolment, according to the University of California Health guide. Cleveland Clinic suggests asking about the duration, the number of visits, the risks and the costs.

Why do treatments need clinical trials at all?

New treatments can only be made widely available after clinical trials show they are safe and effective, as the University of California Health guide explains. Trials are the route from a lab idea to a treatment people can use.